This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
10 September 2013
In the version of this article initially published, the name of the company BDO should have been given as BDO USA (Chicago) and not BDO (Brussels). The error has been corrected in the HTML and PDF versions of the article.
01 December 2013
Nat. Biotechnol. 31, 697–703 (2013); doi:10.1038/nbt.2653; published online 8 August 2013; corrected after print 10 September 2013 In the version of this article initially published, the name of the company BDO should have been given as BDO USA (Chicago) and not BDO (Brussels). The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Supplementary information
Supplementary Text and Figures
Supplementary Table 1 (XLS 141 kb)
Rights and permissions
About this article
Cite this article
Huggett, B. Public biotech 2012—the numbers. Nat Biotechnol 31, 697–703 (2013). https://doi.org/10.1038/nbt.2653
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2653
This article is cited by
-
Bringing up baby
Nature Biotechnology (2018)
-
Raising financing through strategic timing
Nature Nanotechnology (2017)
-
Rheumatoide Arthritis
Zeitschrift für Rheumatologie (2017)
-
Third-quarter biotech job picture
Nature Biotechnology (2015)
-
Fourth-quarter biotech job picture
Nature Biotechnology (2014)